RIL
SYRE icon

Rothschild Investment LLC’s Spyre Therapeutics SYRE Stock Holding History

Rothschild Investment LLC’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.79K Hold
99
– – ﹤0.01% 1962
2026
Q1 		$4.99K Buy
99
+17
+21% +$641 ﹤0.01% 2048
2025
Q4 		$2.69K Buy
82
+2
+3% +$52 ﹤0.01% 2213
2025
Q3 		$1.34K Sell
80
-60
-43% -$978 ﹤0.01% 2455
2025
Q2 		$2.1K Buy
140
+90
+180% +$1.33K ﹤0.01% 2046
2025
Q1 		$807 Buy
50
+10
+25% +$208 ﹤0.01% 2453
2024
Q4 		$931 Hold
40
– – ﹤0.01% 2256
2024
Q3 		$1.18K Buy
40
+35
+700% +$975 ﹤0.01% 2051
2024
Q2 		$118 Buy
+5
New +$169 ﹤0.01% 2684

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Rothschild Investment LLC's SYRE Position: Q2 2026 in Review

Rothschild Investment LLC held its Spyre Therapeutics (SYRE) position steady in Q2 2026 at 99 shares worth $8.79K. The position accounts for ﹤0.01% of the portfolio, ranked #1962.

Rothschild Investment LLC first reported a position in SYRE in Q2 2024 and has held it in 9 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Rothschild Investment LLC held 99 shares of Spyre Therapeutics worth $8.79K as of Q2 2026.
  • Rothschild Investment LLC left its Spyre Therapeutics share count unchanged in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1962 holding.
  • Rothschild Investment LLC first reported a position in Spyre Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.